TY - JOUR
T1 - A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection
AU - Sakabe, Saori
AU - Iwatsuki-Horimoto, Kiyoko
AU - Horimoto, Taisuke
AU - Nidom, Chairul A.
AU - Quynh Le, Mai thi
AU - Takano, Ryo
AU - Kubota-Koketsu, Ritsuko
AU - Okuno, Yoshinobu
AU - Ozawa, Makoto
AU - Kawaoka, Yoshihiro
N1 - Funding Information:
We thank Susan Watson for editing the manuscript. This work was supported by a Grant-in-Aid for Specially Promoted Research, by a contract research fund for the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases from the Ministry of Education, Culture, Sports, Science, and Technology , by grants-in-aid from the Ministry of Health and by ERATO (Japan Science and Technology Agency), by National Institute of Allergy and Infectious Diseases Public Health Service research grants, and by an NIAID-funded Center for Research on Influenza Pathogenesis (CRIP, HHSN266200700010C). Saori Sakabe is supported by a Research Fellowship of the Japan Society for the Promotion of Science for Young Scientists.
PY - 2010/12
Y1 - 2010/12
N2 - A novel influenza (H1N1) virus caused an influenza pandemic in 2009, while highly pathogenic H5N1 avian influenza viruses have continued to infect humans since 1997. Influenza, therefore, remains a serious health threat. Currently, neuraminidase (NA) inhibitors are the mainstay for influenza therapy; however, drug-resistant mutants of seasonal H1N1 and H5N1 viruses have emerged highlighting the need for alternative therapeutic approaches. One such approach is antibody immunotherapy. Here, we show that the monoclonal antibody C179, which recognizes a neutralizing epitope common among H1, H2, H5, and H6 hemagglutinins (HAs), protected mice from a lethal challenge with various H5N1 and pandemic (H1N1) 2009 viruses when administered either intraperitoneally or intranasally. The protective efficacy of intranasally inoculated C179 was comparable to that of intraperitoneal administration. Our results suggest that direct administration of this anti-influenza antibody to viral replication sites is an effective strategy for prophylaxis and therapy.
AB - A novel influenza (H1N1) virus caused an influenza pandemic in 2009, while highly pathogenic H5N1 avian influenza viruses have continued to infect humans since 1997. Influenza, therefore, remains a serious health threat. Currently, neuraminidase (NA) inhibitors are the mainstay for influenza therapy; however, drug-resistant mutants of seasonal H1N1 and H5N1 viruses have emerged highlighting the need for alternative therapeutic approaches. One such approach is antibody immunotherapy. Here, we show that the monoclonal antibody C179, which recognizes a neutralizing epitope common among H1, H2, H5, and H6 hemagglutinins (HAs), protected mice from a lethal challenge with various H5N1 and pandemic (H1N1) 2009 viruses when administered either intraperitoneally or intranasally. The protective efficacy of intranasally inoculated C179 was comparable to that of intraperitoneal administration. Our results suggest that direct administration of this anti-influenza antibody to viral replication sites is an effective strategy for prophylaxis and therapy.
KW - H5N1
KW - Monoclonal antibody Immunotherapy
KW - Pandemic (H1N1) 2009
UR - http://www.scopus.com/inward/record.url?scp=78650231989&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2010.09.007
DO - 10.1016/j.antiviral.2010.09.007
M3 - Article
C2 - 20849879
AN - SCOPUS:78650231989
SN - 0166-3542
VL - 88
SP - 249
EP - 255
JO - Antiviral Research
JF - Antiviral Research
IS - 3
ER -